Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$93.36 USD
+0.54 (0.58%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $93.34 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$93.36 USD
+0.54 (0.58%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $93.34 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
Blueprint Medicines (BPMC) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
Blueprint Medicines (BPMC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Blueprint Medicines Expediates Filings for Key Candidates
by Zacks Equity Research
Blueprint Medicines (BPMC) revs up the regulatory filling plans for its cancer candidates, avapritinib and BLU-667.
5 Cancer-Fighting Stocks to Boost Portfolio Gains
by Swarup Gupta
It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.
Earnings Preview: Blueprint Medicines (BPMC) Q4 Earnings Expected to Decline
by Zacks Equity Research
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines (BPMC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -5.73% and -45.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 52.67% and 1199.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Intuitive Surgical (ISRG) Disappoint in Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical (ISRG) is expected to witness growth across da Vinci Surgical and Service segments. Instruments and accessories revenues are also expected to increase year over year.
Company News For Dec 12, 2017
by Zacks Equity Research
Companies in the news are: KMG,ARGX,BPMC,BLUE
Blueprint Medicines (BPMC) Shows Strength: Stock Adds 9.6% in Session
by Zacks Equity Research
Blueprint Medicines Corporation (BPMC) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
3 Biotech Stocks That Are Broker Favorites
by Arpita Dutt
These 3 biotech stocks have been given a Strong Buy or Buy rating by 80% or more brokers and sport a favorable Zacks Rank #1 (Strong Buy) or #2 (Buy).
Can The Uptrend Continue for Blueprint Medicines (BPMC)?
by Zacks Equity Research
Investors certainly have to be happy with Blueprint Medicines Corporation (BPMC) and its short term performance
Should You Buy Blueprint Medicines (BPMC) Ahead of Earnings?
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and Blueprint Medicines Corporation (BPMC) may be one such company.
Zimmer Biomet (ZBH) Q4 Earnings: A Surprise in the Cards?
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) is expected to report fourth-quarter 2017 financial numbers on Jan 31, before the opening bell.
Quest Diagnostics (DGX) Q4 Earnings: What Lies in Store?
by Zacks Equity Research
Quest Diagnostics Inc. (DGX) is scheduled to report fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 26, 2017.
Mead Johnson (MJN) Q4 Earnings: Disappointment in Store?
by Zacks Equity Research
Mead Johnson Nutrition Company (MJN) is scheduled to report fourth-quarter 2016 results on Jan 26, before the opening bell.
ResMed (RMD) Q2 Earnings: Disappointment in the Cards?
by Zacks Equity Research
ResMed Inc. (RMD) is slated to report second-quarter fiscal 2017 results, after market close on Jan 23.
Blueprint Medicines (BPMC) Shares March Higher, Can It Continue?
by Zacks Equity Research
Blueprint Medicines Corporation (BPMC) has been on the move lately as the stock has risen by 10.8% in the past four weeks, and it is currently trading well above its 20-Day SMA
New Strong Buy Stocks for December 28th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday